Last C$0.34 CAD
Change Today +0.02 / 6.25%
Volume 498.8K
SDI On Other Exchanges
As of 4:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

spectral diagnostics inc (SDI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - C$0.68
52 Week Low
03/19/14 - C$0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

spectral diagnostics inc (SDI) Related Businessweek News

No Related Businessweek News Found

spectral diagnostics inc (SDI) Details

Spectral Diagnostics Inc. develops and commercializes theranostic treatment for severe sepsis in North America. The company’s products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. It is also involved in the development, production, and marketing of recombinant cardiac proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. The company was founded in 1991 and is headquartered in Toronto, Canada.

20 Employees
Last Reported Date: 03/27/14
Founded in 1991

spectral diagnostics inc (SDI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$424.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: C$265.6K
Vice President of Clinical Development
Total Annual Compensation: C$201.8K
Vice President of Sales and Marketing
Total Annual Compensation: C$117.8K
Compensation as of Fiscal Year 2013.

spectral diagnostics inc (SDI) Key Developments

Spectral Diagnostics Inc. Presents Analysis of Japanese Registry Data on Significant Mortality Rate Reduction in Patients with Septic Shock Treated with Toraymyxin

Spectral Diagnostics Inc. announced the presentation of the analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM). The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design. The study, conducted by Dr. M. Iwagami of the University of Tokyo in Japan and supported by the Japanese government, reviewed the Japanese Diagnosis Procedure Combination Database (based on the ICD-10 international classification) and compared 1,116 patients with septic shock treated with PMX who also received continuous renal replacement therapy to 1,115 patients with septic shock who were treated with CRRT only. CRRT is a form of dialysis reserved for some of the sickest patients in intensive care units. The mortality rate of patients treated with two PMX cartridges was 34.5% compared to 47.0% in the untreated group, representing an approximate 25% relative reduction in mortality at 28 days. The authors contrasted these results with those of a study they had conducted one year earlier, in which they evaluated the effect of PMX treatment on a cohort of less severe septic patients and found little difference in survival rates between the treated and untreated groups. The authors concluded, in their presentation at the American Society of Nephrology, that PMX therapy is most effective in patients at the higher risk of death. Furthermore, they noted that those patients who were treated with two PMX cartridges demonstrated a more meaningful benefit versus those treated with only one cartridge. This is the same treatment methodology used in the EUPHRATES trial.

Spectral Diagnostics Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Spectral Diagnostics Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of CAD 643,000 against CAD 679,000 a year ago. Operating loss was CAD 2,012,000 against CAD 2,533,000 a year ago. Loss and comprehensive loss for the period was CAD 2,012,000 or CAD 0.01 basic and diluted per share against CAD 2,517,000 or CAD 0.02 basic and diluted per share a year ago. For the nine months, the company reported revenue of CAD 2,265,000 against CAD 1,959,000 a year ago. Operating loss was CAD 7,638,000 against CAD 7,708,000 a year ago. Loss and comprehensive loss for the period was CAD 7,638,000 or CAD 0.05 basic and diluted per share against CAD 7,659,000 or CAD 0.06 basic and diluted per share a year ago. Net cash used in operating activities was CAD 8,359,000 against CAD 6,853,000 a year ago. Property, plant and equipment expenditures was CAD 47,000 against CAD 281,000 a year ago.

Spectral Diagnostics Inc. Announces Board Changes

Spectral Diagnostics Inc. announced that Mr. William Stevens has been appointed to its Board of Directors. Mr. Stevens brings over 20 years of experience in the investment industry to Spectral. He has held senior roles in investment banking and private equity and has a successful track record of value creation for shareholders. In addition, Mr. Laine Woollard QC, a director of the company since 2010, has resigned from the Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SDI:CN C$0.34 CAD +0.02

SDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SDI.
View Industry Companies

Industry Analysis


Industry Average

Valuation SDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.6x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRAL DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at